7 theories on the future of biotechnology

Despite its already visible achievements, biotechnology often remains overshadowed by technologies such as artificial intelligence in the public perception. However, it is biotechnological processes that enable us to intervene deeply in the molecular biological processes of life and use them in a targeted manner, such as manufacturing biopharmaceutical active ingredients, developing sustainable materials, or optimizing industrial processes.

In recent years, biotechnology has developed into a cross-sectional technology with enormous economic significance. Today, its applications extend far beyond the medical field and encompass almost all branches of industry. These range from agriculture and energy production to the food and chemical industries, pharmaceuticals, and environmental technology.

Scientifically, this range is based on the ability to specifically control cellular and molecular processes and make them technically usable. In practice, this means, for example:

• the development of innovative therapeutics (e.g., mRNA vaccines, monoclonal antibodies),
• the production of cell culture-based foods as part of sustainable food systems,
• the use of enzyme technologies in chemical recycling,
• or the use of biological pesticides and optimized microorganisms to increase agricultural yields.

Biotechnology is also used in security-sensitive areas, such as the development of biosensors or protective vaccines against biological threats.

The past few years have already brought incredible progress for biotechnology. But what will happen next? What will become important—and what does that mean for a company like RENOLIT?

I have seven theories on this.

My first and most important thesis is the following: despite groundbreaking successes (such as mRNA vaccines, monoclonal antibodies, and CRISPR—the targeted modification of DNA in viruses and bacteria), we are still in the early stages of a technological revolution. The biggest quantum leaps are yet to come.

One example: several pharmaceutical companies are currently working on vaccines against cancer. This would be an unprecedented medical blessing, only possible through biotechnology.

This makes biotechnology an increasingly important field for us. Those who get involved in this field can help shape the future, comparable to the digital revolution of the 1990s.

The cancer vaccines described above will likely need to be customized for each patient. This example is not the only one that shows that the demand for individualized therapies and tailor-made medicinal products will continue to rise in the future.

Advances in precision medicine make it possible to tailor therapies to individual genetic profiles. This requires platform technologies for personalized medicine production, e.g., cell-based therapies or vaccines against cancer.

Microfluidic systems, lab-on-a-chip technologies, and mini bioreactors are crucial in ensuring the necessary flexibility—a field that increasingly demands innovations in materials science, such as smart polymer films.

With the growing demand for personalized medicine, traditional mass production models will reach their limits. Instead, decentralized, modular production systems are gaining in importance—especially for supplying remote or infrastructure-poor regions.

Point-of-care manufacturing approaches based on scalable bioreactors and automated systems enable the production of medicines directly at the point of treatment. This is a development with enormous social and economic implications.

Single-use bioreactors—made from high-quality polymer materials—have proven to be flexible, fast, and cost-effective. They reduce the risk of cross-contamination, lower energy and water consumption (no cleaning cycles), and shorten time to market.

In biopharmaceuticals, the proportion of single-use systems in pilot and production plants is already high – and rising.

With sustainability becoming increasingly important, biotechnology will also have to develop more sustainable production methods. Biotechnology itself must become more sustainable, a contradiction that can be overcome through biodegradable materials, recyclable systems, and the integration of circular economy principles. At the same time, it enables green innovations in other areas, e.g., through bio-based plastics, enzymatic recycling, or CO₂ utilization.

The integration of AI-supported process control, predictive maintenance, and digital twins makes biotechnological processes more precise, faster, and more efficient. In pharmaceutical research, AI accelerates drug screening, modeling, and production optimization.

The future belongs to intelligent bioreactors equipped with sensors, AI algorithms, and data analysis platforms.

The global biotechnology market is growing at double-digit rates every year—in Germany, the focus is still very much on research, but the potential for industrial scaling is huge. Successful examples such as BioNTech show how strong the added value of biotechnological innovation can be—when science, entrepreneurship, and politics work together.

With targeted investment, improved regulatory conditions and an innovation-friendly industrial policy, biotechnology can become a key growth area for Europe as a business hub.

Biotechnology is a key technology that can address not only medical challenges, but also ecological and industrial ones. RENOLIT will be investing specifically in biotechnological applications and materials in the coming years – with a focus on innovation, sustainability, and competitiveness. At the same time, we would like to gain more attention and support from politicians and society for this highly relevant area of technology.

Biotechnology is not a dream for the future – it is the future. Let's make the most of this opportunity.